MINNEAPOLIS, Jan. 16,
2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:
TECH) today announced that management will host a conference call
and webcast on Thursday, February 1,
2024, at 8:00 a.m. CST to
review second quarter fiscal 2024 financial results.
Access to the discussion may be obtained as follows:
Time:
|
8:00 a.m.
CST
|
Date:
|
February 1,
2024
|
Dial-in:
|
1-877-407-9208 or
1-201-493-6784 (for international callers)
|
Conference
ID:
|
13743935
|
Webcast:
|
https://investors.bio-techne.com/ir-calendar
|
A recorded rebroadcast will be available for interested parties
unable to participate in the live conference call by dialing
1-844-512-2921 or 1-412-317-6671 (for international callers) and
referencing Conference ID 13743935.
The replay will be available from 11:00 a.m. CST on Thursday, February 1, 2024, until 11:00 p.m. CST on Friday, March 1, 2024.
Bio-Techne Corporation (NASDAQ: TECH) is a leading
developer and manufacturer of high-quality purified proteins and
reagent solutions - notably cytokines and growth factors,
antibodies, immunoassays, biologically active small molecule
compounds, tissue culture reagents, T-Cell activation and gene
editing technologies. Bio-Techne's product portfolio also includes
protein analysis solutions, sold under the ProteinSimple brand
name, offering researchers efficient and streamlined options for
automated Western blot and multiplexed ELISA workflow. These
reagent and protein analysis solutions are sold to biomedical
researchers as well as clinical research laboratories and
constitute the Protein Sciences Segment. Bio-Techne also develops
and manufactures diagnostic products including FDA-regulated
controls, calibrators, blood gas and clinical chemistry controls
and custom assay development on dedicated clinical instruments.
Bio-Techne's genomic tools include advanced tissue-based in
situ hybridization assays (ISH) for research and clinical use,
sold under the ACD brand, as well as the Lunaphore branded
portfolio of fully automated spatial biology solutions. Its
portfolio also includes molecular diagnostic oncology and carrier
screening assays. These diagnostic and genomic products comprise
Bio-Techne's Diagnostics and Genomics Segment. Bio-Techne products
are integral components of scientific investigations into
biological processes and molecular diagnostics, revealing the
nature, diagnosis, etiology and progression of specific diseases.
They aid in drug discovery efforts and provide the means for
accurate clinical tests and diagnoses. With thousands of products
in its portfolio, Bio-Techne generated over $1.1 billion in net sales in fiscal 2023 and has
approximately 3,100 employees worldwide.
Contact:
|
David Clair, Vice
President, Investor Relations & Corporate
Development
|
|
david.clair@bio-techne.com
|
|
612-656-4416
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-host-conference-call-on-february-1-2024-to-announce-second-quarter-fiscal-2024-financial-results-302035030.html
SOURCE Bio-Techne Corporation